Sugi Predict

Sugi Predict / Compounds / SCHEMBL264637

SCHEMBL264637

SCHEMBL264637

CNS(=O)(=O)c1cccc(Br)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNNI3K Q59H18 4/20 0.60
▸ ATM Q13315 1/20 0.53
▸ HSD17B2 P37059 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ EDNRB P24530 2/20 0.51
▸ EDNRA P25101 2/20 0.51
▸ PGR P06401 1/20 0.50
▸ BRD4 O60885 1/20 0.49
▸ WDR5 P61964 1/20 0.49
▸ EGFR P00533 1/20 0.49
▸ LMNA P02545 1/20 0.47
▸ KAT6A Q92794 2/20 0.47
▸ FLT1 P17948 1/20 0.47
▸ FLT4 P35916 1/20 0.47
▸ KDR P35968 1/20 0.47
▸ GAA P10253 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ CTSL P07711 1/20 0.45
▸ CTSS P25774 1/20 0.45
▸ CTSK P43235 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31689440 1.00 TNNI3K (0.60) TNNI3KATMHSD17B2L3MBTL1EDNRB
SCHEMBL2242660 0.85 L3MBTL1 (0.61) TNNI3KL3MBTL1EGFRLMNAGAA
SCHEMBL11962953 0.80 CA1 (0.59) ATMHSD17B2EDNRBEDNRAPGR
SCHEMBL3531211 0.80 ATM (0.53) ATMHSD17B2L3MBTL1EDNRBEDNRA
SCHEMBL420249 0.80 ATM (0.53) ATMHSD17B2L3MBTL1EDNRBEDNRA
SCHEMBL2372604 0.80 ATM (0.53) ATMHSD17B2L3MBTL1EDNRBEDNRA
SCHEMBL265040 0.79 MAPT (0.69) ATMHSD17B2EDNRBEDNRAPGR
SCHEMBL17513498 0.79 ATM (0.60) ATMHSD17B2L3MBTL1EDNRBEDNRA
SCHEMBL265556 0.79 HSD17B2 (0.49) ATMHSD17B2L3MBTL1EDNRBEDNRA
SCHEMBL3566598 0.79 PGR (0.50) TNNI3KATMHSD17B2L3MBTL1EDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110857301-B Method for preparing TNNI3K inhibitor 南京理工大学 2022-07-22 — — CN claimed
CN-109422748-B Method for synthesizing TNNI3K inhibitor 南京理工大学 2021-06-22 — — CN claimed
CN-110857301-A Method for preparing TNNI3K inhibitor 南京理工大学 2020-03-03 — — CN claimed
EP-2547204-A2 ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS Bayer Intellectual Property GmbH (DE) 2013-01-23 — — EP claimed
US-20110230350-A1 ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2011-09-22 — — US claimed
WO-2011113861-A2 ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2011-09-22 — — WO claimed
EP-4743453-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION Pretzel Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-11-06 — — US disclosed
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-10-16 — — US disclosed
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof Maxymune Therapeutics, Inc. (US) 2025-09-30 — — US disclosed
US-12258314-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2025-03-25 — — US disclosed
WO-2025015178-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION PRETZEL THERAPEUTICS, INC. (US) 2025-01-16 — — WO disclosed
CN-112778276-B Compounds as SHP2 inhibitors and uses thereof 南京圣和药业股份有限公司 2024-08-20 — — CN disclosed
WO-1998042670-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRA PHARMACEUTICALS LTD. (GB) 1998-10-01 — — WO disclosed
EP-0865431-A2 COMPOUNDS Astra Pharmaceuticals Limited (GB) 1998-09-23 — — EP disclosed
WO-1997020815-A1 COMPOUNDS ASTRA PHARMACEUTICALS LTD. (GB) 1997-06-12 — — WO disclosed
US-5597826-A Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist PFIZER INC. (US) 1997-01-28 — — US disclosed
EP-0701819-A2 Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist PFIZER INC. (US) 1996-03-20 — — EP disclosed
EP-0689536-A1 NAPHTHALENE DERIVATIVES PFIZER INC. (US) 1996-01-03 — — EP disclosed
WO-1994021619-A1 NAPHTHALENE DERIVATIVES PFIZER INC. (US) 1994-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258314-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML TNNI3K 4042/4885ATM 3382/4885HSD17B2 3949/4885
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 TNNI3K 1366/4885ATM 3578/4885HSD17B2 4336/4885
US-20110230350-A1 ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS STS, ARSA, TST TNNI3K 1729/4885ATM 3017/4885HSD17B2 812/4885
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof SLC43A1, SLC7A1, SLC1A5 TNNI3K 1366/4885ATM 3578/4885HSD17B2 4336/4885
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 TNNI3K 1366/4885ATM 3578/4885HSD17B2 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.